Nanoscope Eyes Precision Era for Vision Therapy with New MCO-010 Data

DALLAS, TX – February 24, 2026 – Hopes for a widely applicable treatment for a common form of inherited blindness are sharpening as Nanoscope Therapeutics prepares to unveil a deeper analysis of its groundbreaking optogenetic therapy, MCO-010. The company announced that new findings from its long-term clinical trials will be presented this week at the prestigious 2026 Macula Society Annual Meeting in San Diego.

The presentation, led by Dr. Christine N. Kay, a respected retinal specialist, will detail a multivariant analysis of three-year data from the pivotal RESTORE and REMAIN studies. This post-hoc analysis moves beyond the primary question of whether the therapy works, and instead seeks to answer a more nuanced and clinically vital question: for which patients does it work best? By examining the specific patient and disease characteristics associated with the most significant vision gains, Nanoscope aims to provide clinicians with a roadmap for using MCO-010 in the real world, should it gain regulatory approval.

This step toward precision medicine comes as the Dallas-based biotech advances its rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), positioning MCO-010 as a potential first-in-class, one-time treatment for patients with severe vision loss from retinitis pigmentosa (RP).

Refining Treatment for Retinitis Pigmentosa

Retinitis Pigmentosa is a group of rare, genetic disorders that cause a progressive breakdown and loss of cells in the retina—the light-sensitive tissue at the back of the eye. With over 100 different genetic mutations identified as causes, RP presents a formidable challenge for treatment, slowly robbing patients of their sight, often leading to legal or complete blindness.

Nanoscope’s MCO-010 has shown significant promise in this difficult landscape. The RESTORE Phase 2b/3 trial was a randomized, sham-controlled study that demonstrated statistically significant and clinically meaningful improvements in vision. The subsequent REMAIN extension study confirmed the durability of these effects, with patients maintaining vision gains for up to three years after a single injection. Data showed that patients, on average, maintained a vision gain equivalent to reading three additional lines on an eye chart.

Now, Dr. Kay’s presentation will dissect this landmark dataset. "These analyses are an important next step in helping to understand the Phase 3 clinical trial data of MCO-010 in retinitis pigmentosa," said Dr. Kay, Director of Clinical Research and Retinal Genetics at Vitreoretinal Associates. "By examining the characteristics of patients who had the best outcomes across three years of follow-up in RESTORE and REMAIN, we can begin to understand how the therapy can be used in patients in the real world, if approved."

This level of analysis is critical for a therapy that aims to treat a genetically diverse condition. By identifying predictive biomarkers or clinical characteristics, physicians could one day better select candidates for treatment, manage patient expectations, and optimize outcomes.

A Novel Mechanism to Reactivate Sight

What sets MCO-010 apart is its innovative mechanism of action. It is a gene-agnostic optogenetic therapy. Unlike gene-specific treatments such as Luxturna, which corrects a single genetic defect (RPE65) and requires genetic testing, MCO-010 is designed to work regardless of the patient's underlying mutation.

It achieves this by using a harmless adeno-associated virus (AAV2) to deliver a gene encoding a Multi-Characteristic Opsin (MCO) to the retina. The therapy doesn't target the degenerated photoreceptor cells (rods and cones). Instead, it targets the surviving layer of bipolar retinal cells, which are part of the eye’s remaining visual circuitry. The delivered gene effectively turns these bipolar cells into novel, light-sensing cells. When ambient light enters the eye, these newly photosensitive cells are activated and transmit signals to the brain, restoring a degree of vision.

This approach has several key advantages. It can be used in patients with advanced disease who have already lost most of their photoreceptors. Furthermore, the therapy is administered as a single, in-office intravitreal injection, a common procedure for retinal specialists. Critically, the MCO opsin is sensitive to ambient light, meaning patients do not require cumbersome light-amplifying goggles or external devices to see.

On the Cusp of a Breakthrough

The promising clinical data and innovative mechanism have paved a favorable regulatory path for Nanoscope. The company is actively engaged in a rolling BLA submission with the FDA, a process that allows for completed sections of the application to be submitted and reviewed on an ongoing basis, potentially accelerating the path to approval.

The therapy has already received multiple key designations from the FDA, including Fast Track and Orphan Drug status for both RP and Stargardt disease, highlighting the significant unmet medical need it addresses. The durable efficacy and favorable safety profile—with most adverse events being mild, moderate, and manageable—bolster the case for its approval.

"Dr. Kay's multivariant analyses add a clinically significant dimension to what is already a landmark dataset," stated Dr. Samuel Barone, Chief Medical Officer of Nanoscope Therapeutics. He emphasized the importance of presenting this work at the Macula Society meeting, where leading specialists can "engage directly with the findings as we continue our rolling BLA for MCO-010 – potentially offering the first approved therapy for patients with retinitis pigmentosa having severe vision loss."

A Platform with Broad Horizons

While the immediate focus is on retinitis pigmentosa, Nanoscope’s vision extends far beyond a single disease. The disease-agnostic nature of the MCO platform makes it a versatile tool for tackling other retinal degenerative conditions characterized by photoreceptor loss.

The company has already reported positive results from its STARLIGHT Phase 2 trial of MCO-010 in Stargardt disease, another inherited retinal dystrophy. Based on this success and a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, Nanoscope is planning to initiate a Phase 3 trial for this indication in 2026.

Further expanding its pipeline, Nanoscope also intends to launch a Phase 2 program in 2026 to evaluate MCO therapy for geographic atrophy (GA), the advanced form of dry age-related macular degeneration and a leading cause of blindness in the elderly. With other programs for conditions like Leber congenital amaurosis (LCA) also in development, the MCO platform is positioned as a potential cornerstone technology for vision restoration.

As retinal specialists gather in San Diego, the new data on MCO-010 represents more than just an academic exercise. It marks a crucial step in translating a novel scientific concept into a tangible, refined therapeutic option, bringing a new sense of hope to millions of patients and their families waiting for a breakthrough in the fight against blindness.